All these indicated that blockage of c-Src improve ovarian cancer cells’ sensitivity to paclitaxel under hypoxia, thus c-Src may serve as a promising target to overcome hypoxic resistance to paclitaxel in ovarian cancer. This evidence concerns the gene SRC and ovarian cancer.